Jundishapur Journal of Natural Pharmaceutical Products

Published by: Kowsar

Minocycline is More Potent Than Tetracycline and Doxycycline in Inhibiting MMP-9 in Vitro

Mina Modheji 1 , Samaneh Olapour 2 , Mohammad Javad Khodayar 2 , Ali Jalili 3 and Hamid Yaghooti 4 , *
Authors Information
1 Ahvaz Jundishapur University of Medical Sciences, Ahvaz, IR Iran
2 Department of Pharmacology and Toxicology, School of Pharmacy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, IR Iran
3 Cellular and Molecular Research Center, Kurdistan University of Medical Sciences, Sanandaj, IR Iran
4 Department of Medical Laboratory Sciences, School of Allied Medical Sciences, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, IR Iran
Article information
  • Jundishapur Journal of Natural Pharmaceutical Products: May 01, 2016, 11 (2); e27377
  • Published Online: April 18, 2016
  • Article Type: Research Article
  • Received: March 16, 2015
  • Revised: December 23, 2015
  • Accepted: December 30, 2015
  • DOI: 10.17795/jjnpp-27377

To Cite: Modheji M, Olapour S, Khodayar M J, Jalili A, Yaghooti H. Minocycline is More Potent Than Tetracycline and Doxycycline in Inhibiting MMP-9 in Vitro, Jundishapur J Nat Pharm Prod. 2016 ; 11(2):e27377. doi: 10.17795/jjnpp-27377.

Abstract
Copyright © 2016, School of Pharmacy, Ahvaz Jundishapur University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Materials and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Gross J, Lapiere CM. Collagenolytic activity in amphibian tissues: a tissue culture assay. Proc Natl Acad Sci U S A. 1962; 48: 1014-22[PubMed]
  • 2. Malemud CJ. Matrix metalloproteinases (MMPs) in health and disease: an overview. Front Biosci. 2005; 11: 1696-701[DOI]
  • 3. Hu J, Van den Steen PE, Sang QX, Opdenakker G. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov. 2007; 6(6): 480-98[DOI][PubMed]
  • 4. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res. 2003; 92(8): 827-39[DOI][PubMed]
  • 5. Van den Steen PE, Dubois B, Nelissen I, Rudd PM, Dwek RA, Opdenakker G. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit Rev Biochem Mol Biol. 2002; 37(6): 375-536[DOI][PubMed]
  • 6. Zeng B, Prasan A, Fung KC, Solanki V, Bruce D, Freedman SB, et al. Elevated circulating levels of matrix metalloproteinase-9 and -2 in patients with symptomatic coronary artery disease. Intern Med J. 2005; 35(6): 331-5[DOI][PubMed]
  • 7. Schmalfeldt B, Prechtel D, Harting K, Spathe K, Rutke S, Konik E, et al. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin Cancer Res. 2001; 7(8): 2396-404[PubMed]
  • 8. Burrage PS, Mix KS, Brinckerhoff CE. Matrix metalloproteinases: role in arthritis. Front Biosci. 2006; 11(1): 529-43[DOI]
  • 9. Dorman G, Cseh S, Hajdu I, Barna L, Konya D, Kupai K, et al. Matrix metalloproteinase inhibitors: a critical appraisal of design principles and proposed therapeutic utility. Drugs. 2010; 70(8): 949-64[DOI][PubMed]
  • 10. Griffin MO, Fricovsky E, Ceballos G, Villarreal F. Tetracyclines: a pleitropic family of compounds with promising therapeutic properties. Review of the literature. Am J Physiol Cell Physiol. 2010; 299(3)-48[DOI][PubMed]
  • 11. Hu X, Wu B, Wang X, Xu C, He B, Cui B, et al. Minocycline attenuates ischemia-induced ventricular arrhythmias in rats. Eur J Pharmacol. 2011; 654(3): 274-9[DOI][PubMed]
  • 12. Thompson RW, Golub LM. Treatment of aortic and vascular aneurysms with tetracycline compounds. 1998;
  • 13. Wang Y, Morlandt AB, Xu X, Carnes DJ, Chen Z, Steffensen B. Tetracycline at subcytotoxic levels inhibits matrix metalloproteinase-2 and -9 but does not remove the smear layer. J Periodontol. 2005; 76(7): 1129-39[DOI][PubMed]
  • 14. Sapadin AN, Fleischmajer R. Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol. 2006; 54(2): 258-65[DOI][PubMed]
  • 15. Machado LS, Kozak A, Ergul A, Hess DC, Borlongan CV, Fagan SC. Delayed minocycline inhibits ischemia-activated matrix metalloproteinases 2 and 9 after experimental stroke. BMC Neurosci. 2006; 7: 56[DOI][PubMed]
  • 16. Nagel S, Su Y, Horstmann S, Heiland S, Gardner H, Koziol J, et al. Minocycline and hypothermia for reperfusion injury after focal cerebral ischemia in the rat: effects on BBB breakdown and MMP expression in the acute and subacute phase. Brain Res. 2008; 1188: 198-206[DOI][PubMed]
  • 17. Toth M, Fridman R. Assessment of gelatinases (MMP-2 and MMP-9 by gelatin zymography. 2001; : 163-74
  • 18. Lee CZ, Yao JS, Huang Y, Zhai W, Liu W, Guglielmo BJ, et al. Dose–response effect of tetracyclines on cerebral matrix metalloproteinase-9 after vascular endothelial growth factor hyperstimulation. J Cereb Blood Flow Metab. 2006; 26(9): 1157-64[DOI]
  • 19. Yao JS, Shen F, Young WL, Yang GY. Comparison of doxycycline and minocycline in the inhibition of VEGF-induced smooth muscle cell migration. Neurochem Int. 2007; 50(3): 524-30[DOI][PubMed]
  • 20. Ryan ME, Usman A, Ramamurthy NS, Golub LM, Greenwald RA. Excessive matrix metalloproteinase activity in diabetes: inhibition by tetracycline analogues with zinc reactivity. Curr Med Chem. 2001; 8(3): 305-16[PubMed]
  • 21. Curci JA, Petrinec D, Liao S, Golub LM, Thompson RW. Pharmacologic suppression of experimental abdominal aortic aneurysms: a comparison of doxycycline and four chemically modified tetracyclines. J Vasc Surg. 1998; 28(6): 1082-93[DOI]
  • 22. Cazalis J, Tanabe S, Gagnon G, Sorsa T, Grenier D. Tetracyclines and chemically modified tetracycline-3 (CMT-3) modulate cytokine secretion by lipopolysaccharide-stimulated whole blood. Inflammation. 2009; 32(2): 130-7[DOI][PubMed]
  • 23. Bannikov GA, Lakritz J, Premanandan C, Mattoon JS, Abrahamsen EJ. Kinetics of inhibition of purified bovine neutrophil matrix metalloproteinase 9 by low-molecular-weight inhibitors. Am J Vet Res. 2009; 70(5): 633-9[DOI][PubMed]
  • 24. Sadowski T, Steinmeyer J. Effects of tetracyclines on the production of matrix metalloproteinases and plasminogen activators as well as of their natural inhibitors, tissue inhibitor of metalloproteinases-1 and plasminogen activator inhibitor-1. Inflamm Res. 2001; 50(3): 175-82[PubMed]
  • 25. Greenwald RA, Golub LM, Ramamurthy NS, Chowdhury M, Moak SA, Sorsa T. In vitro sensitivity of the three mammalian collagenases to tetracycline inhibition: relationship to bone and cartilage degradation. Bone. 1998; 22(1): 33-8[DOI]
  • 26. Gilbertson-Beadling S, Powers EA, Stamp-Cole M, Scott PS, Wallace TL, Copeland J, et al. The tetracycline analogs minocycline and doxycycline inhibit angiogenesis in vitro by a non-metalloproteinase-dependent mechanism. Cancer Chemother Pharmacol. 1995; 36(5): 418-24[DOI][PubMed]
  • 27. Burns FR, Stack MS, Gray RD, Paterson CA. Inhibition of purified collagenase from alkali-burned rabbit corneas. Invest Ophthalmol Vis Sci. 1989; 30(7): 1569-75[PubMed]
  • 28. Garrido-Mesa N, Zarzuelo A, Galvez J. What is behind the non-antibiotic properties of minocycline? Pharmacol Res. 2013; 67(1): 18-30[DOI][PubMed]
  • 29. Romero-Perez D, Fricovsky E, Yamasaki KG, Griffin M, Barraza-Hidalgo M, Dillmann W, et al. Cardiac uptake of minocycline and mechanisms for in vivo cardioprotection. J Am Coll Cardiol. 2008; 52(13): 1086-94[DOI][PubMed]
  • 30. Bahrami F, Morris DL, Pourgholami MH. Tetracyclines: drugs with huge therapeutic potential. Mini Rev Med Chem. 2012; 12(1): 44-52[PubMed]
  • 31. Griffin MO, Ceballos G, Villarreal FJ. Tetracycline compounds with non-antimicrobial organ protective properties: possible mechanisms of action. Pharmacol Res. 2011; 63(2): 102-7[DOI][PubMed]
  • 32. Castro MM, Kandasamy AD, Youssef N, Schulz R. Matrix metalloproteinase inhibitor properties of tetracyclines: therapeutic potential in cardiovascular diseases. Pharmacol Res. 2011; 64(6): 551-60[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments